Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.

Journal of hepatology - 1 Jan 2010

Moreno Christophe, Deltenre Pierre, Pawlotsky Jean-Michel, Henrion Jean, Adler Michael, Mathurin Philippe

Abstract excerpt

BACKGROUND & AIMS: In hepatitis C virus genotype 1 (HCV-1) patients with a rapid viral decline within the first month of therapy, a 24-week course of pegylated interferon (PEG-IFN) alpha and ribavirin treatment has been claimed to be as efficient as the standard 48-week duration. METHODS: We performed a meta-analysis of 7 randomized controlled trials comparing less than 48 weeks to 48 weeks PEG-IFN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 19931204
DOI: 10.1016/j.jhep.2009.10.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.PMID 19931204Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.Semantic proximity Read ↗

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?Semantic proximity Read ↗

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.Semantic proximity Read ↗

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review.Semantic proximity Read ↗

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.Semantic proximity Read ↗

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.